RxDoctor Payments Data

Nicholas Talluri, MD

Adult Reconstructive Orthopaedic Surgery · Sarasota, FLNPI 1114314705

Payments from drug & device makers

$5,158in general payments, 2019–2025

Across 72 payments — averaging $71.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$3K
  • Zimmer Biomet$2K
  • Smith+Nephew$127
  • Vifor Pharma, Inc.$114
  • MVP Orthopedics Inc$65
  • Johnson & Johnson$25
  • plus $42 from 3 others

What the payments were for

  • Travel & lodging$98619%
  • Food & beverage$4,17281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker52$2,623
Zimmer Biomet9$2,162
Smith+Nephew3$127
Vifor Pharma, Inc.1$114
MVP Orthopedics Inc3$65
Johnson & Johnson1$25
Coastal Medical Technologies LLC1$21
Medtronic1$16
Heraeus Medical, LLC.1$5

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,158 in reported general payments places this provider in the 30th percentile of 96 adult reconstructive orthopaedic surgery providers in Florida.

See all adult reconstructive orthopaedic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$630,404
Medicare patients
1,117
Services billed
7,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban11$4,862
EliquisApixaban15$2,896
Diclofenac Sodium287$2,066
Oxycodone Hcl349$1,761
Omeprazole219$1,154
Ondansetron Hcl252$1,150
Meloxicam268$783
Tramadol Hcl200$775
Methylprednisolone66$408
Celecoxib38$314
Amoxicillin148$310
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$278
Gabapentin24$144
Hydromorphone Hcl17$101
Clindamycin Hcl12$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$25$4,86211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 96 adult reconstructive orthopaedic surgery providers in Florida.

Other adult reconstructive orthopaedic surgery in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →